Genetics and Heart Failure: A Concise Guide for the Clinician

The pathogenesis of heart failure involves a complex interaction between genetic and environmental factors. Genetic factors may influence the susceptibility to the underlying etiology of heart failure, the rapidity of disease progression, or the response to pharmacologic therapy. The genetic contribution to heart failure is relatively minor in most multifactorial cases, but more direct and profound in the case of familial dilated cardiomyopathy. Early studies of genetic risk for heart failure focused on polymorphisms in genes integral to the adrenergic and renin-angiotensin-aldosterone system. Some of these variants were found to increase the risk of developing heart failure, and others appeared to affect the therapeutic response to neurohormonal antagonists. Regardless, each variant individually confers a relatively modest increase in risk and likely requires complex interaction with other variants and the environment for heart failure to develop. Dilated cardiomyopathy frequently leads to heart failure, and a genetic etiology increasingly has been recognized in cases previously considered to be “idiopathic”. Up to 50% of dilated cardiomyopathy cases without other cause likely are due to a heritable genetic mutation. Such mutations typically are found in genes encoding sarcomeric proteins and are inherited in an autosomal dominant fashion. In recent years, rapid advances in sequencing technology have improved our ability to diagnose familial dilated cardiomyopathy and those diagnostic tests are available widely. Optimal care for the expanding population of patients with heritable heart failure involves counselors and physicians with specialized training in genetics, but numerous online genetics resources are available to practicing clinicians.

[1]  Heidi L Rehm,et al.  Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era. , 2013, The Journal of molecular diagnostics : JMD.

[2]  E. McNally,et al.  Genetic mutations and mechanisms in dilated cardiomyopathy. , 2013, The Journal of clinical investigation.

[3]  Donald Wolfgeher,et al.  Population-Based Variation in Cardiomyopathy Genes , 2012, Circulation. Cardiovascular genetics.

[4]  Deborah A Nickerson,et al.  Evaluating Pathogenicity of Rare Variants From Dilated Cardiomyopathy in the Exome Era , 2012, Circulation. Cardiovascular genetics.

[5]  Nicole M. Johnson,et al.  Genetic testing for dilated cardiomyopathy in clinical practice. , 2012, Journal of cardiac failure.

[6]  D. Lanfear,et al.  Pharmacogenetics in Chronic Heart Failure: New Developments and Current Challenges , 2012, Current Heart Failure Reports.

[7]  L. Mestroni,et al.  Truncations of titin causing dilated cardiomyopathy. , 2012, The New England journal of medicine.

[8]  A. Zwinderman,et al.  Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. , 2012, Journal of the American College of Cardiology.

[9]  J. Lupski,et al.  Human genome sequencing in health and disease. , 2012, Annual review of medicine.

[10]  G. Dorn,et al.  Clinical considerations of heritable factors in common heart failure. , 2011, Circulation. Cardiovascular genetics.

[11]  R. Hershberger,et al.  Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. , 2011, Journal of the American College of Cardiology.

[12]  Joel N Hirschhorn,et al.  Genome-wide association studies: results from the first few years and potential implications for clinical medicine. , 2011, Annual review of medicine.

[13]  E. Boerwinkle,et al.  Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients , 2011, Pharmacogenetics and genomics.

[14]  Eric Boerwinkle,et al.  Association of Genome-Wide Variation With the Risk of Incident Heart Failure in Adults of European and African Ancestry: A Prospective Meta-Analysis From the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium , 2010, Circulation. Cardiovascular genetics.

[15]  T. Callis,et al.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all , 2010, Expert review of molecular diagnostics.

[16]  Joseph T. Glessner,et al.  Common Variants in HSPB7 and FRMD4B Associated With Advanced Heart Failure , 2010, Circulation. Cardiovascular genetics.

[17]  F. Chiang,et al.  Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure , 2010, The Pharmacogenomics Journal.

[18]  D. Judge Use of genetics in the clinical evaluation of cardiomyopathy. , 2009, JAMA.

[19]  C. Patterson A Good Idea: A Physician’s Perspective on Genetic Counseling for Hypertrophic Cardiomyopathy , 2009, Journal of cardiovascular translational research.

[20]  S. Kardia,et al.  Clinical and genetic modifiers of long-term survival in heart failure. , 2009, Journal of the American College of Cardiology.

[21]  Ana Morales,et al.  Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2009, Circulation. Heart failure.

[22]  F. Collins,et al.  The HapMap and genome-wide association studies in diagnosis and therapy. , 2009, Annual review of medicine.

[23]  Sekar Kathiresan,et al.  HapMap and Mapping Genes for Cardiovascular Disease , 2008, Circulation. Cardiovascular genetics.

[24]  E. Bleecker,et al.  A polymorphism of G-protein coupled receptor kinase5 alters agonist-promoted desensitization of beta2-adrenergic receptors. , 2008, Pharmacogenetics and genomics.

[25]  J. Spertus,et al.  A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure , 2008, Nature Medicine.

[26]  S. Kardia,et al.  Abstract 2001: Genetic {beta}-Blockade: A G-Protein Coupled Receptor Kinase-5 Polymorphism That Inhibits Beta-Adrenergic Receptor Signaling is Protective in Heart Failure , 2006 .

[27]  D. Conrad,et al.  A worldwide survey of haplotype variation and linkage disequilibrium in the human genome , 2006, Nature Genetics.

[28]  D. Levy,et al.  Association of parental heart failure with risk of heart failure in offspring. , 2006, The New England journal of medicine.

[29]  R. Bennett,et al.  A New Definition of Genetic Counseling: National Society of Genetic Counselors’ Task Force Report , 2006, Journal of Genetic Counseling.

[30]  G. MacGowan,et al.  Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. , 2004, Journal of the American College of Cardiology.

[31]  Tianlun Yang,et al.  Association of the angiotensin‐converting enzyme gene polymorphism with chronic heart failure in Chinese Han patients , 2004, European journal of heart failure.

[32]  G. Dorn,et al.  β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure , 2003, Nature Medicine.

[33]  S. Ball,et al.  An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study , 2003, European journal of heart failure.

[34]  V. Cameron,et al.  Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. , 2003, Journal of the American College of Cardiology.

[35]  P. Insel,et al.  Blunted Cardiac Responses to Receptor Activation in Subjects With Thr164Ile &bgr;2-Adrenoceptors , 2001, Circulation.

[36]  T. McIntosh,et al.  The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. , 1998, The Journal of clinical investigation.

[37]  S. Green,et al.  Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Sylvén,et al.  The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. , 1996, Journal of the American College of Cardiology.

[39]  N. Iwai,et al.  DD Genotype of the Angiotensin‐Converting Enzyme Gene Is a Risk Factor for Left Ventricular Hypertrophy , 1994, Circulation.

[40]  T. Ogihara,et al.  Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. , 1994, The New England journal of medicine.

[41]  H. Schunkert,et al.  Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. , 1994, The New England journal of medicine.

[42]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[43]  F. Sanger,et al.  Sequence and organization of the human mitochondrial genome , 1981, Nature.

[44]  W. Belloso,et al.  [Cardiovascular pharmacogenomics]. , 2014, Archivos de cardiologia de Mexico.

[45]  H. Watkins,et al.  The Genomic Architecture of Sporadic Heart Failure , 2011 .

[46]  C. O’Donnell,et al.  Genomics of heart failure. , 2010, Heart failure clinics.

[47]  Joseph T. Glessner,et al.  Common Variants in HSPB 7 and FRMD 4 B Associated With Advanced Heart Failure , 2010 .

[48]  Julie A. Johnson,et al.  Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. , 2007, Pharmacogenetics and genomics.

[49]  L. Lazzeroni,et al.  A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. , 2006, Proceedings of the National Academy of Sciences of the United States of America.